

In the Claims:

Please amend the claims to read as follows (detail of claim amendments included herewith):

61. (Amended) An isolated polypeptide comprising a member selected from the group consisting of

- (a) the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4; and
- (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of SEQ ID NO:2 or SEQ ID NO:4;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response to a polypeptide having the sequence of SEQ ID NO:2 or SEQ ID NO:4.

67. (Amended) An immunogenic composition comprising the polypeptide of Claim 61 and a pharmaceutically acceptable carrier.

68. (Amended) The immunogenic composition of Claim 67, wherein said immunogenic composition further comprises at least one other *Moraxella catarrhalis* antigen.